Oizumi K, Miyamoto M, Koike H
Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Jpn J Pharmacol. 1990 Jun;53(2):264-6. doi: 10.1254/jjp.53.264.
CS-905, (+-)-3-(1-diphenylmethylazetidin-3-yl)5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxy lat e, is a novel dihydropyridine calcium blocker. Both CS-905 and nicardipine, when administered orally, produced a dose-dependent fall of blood pressure in conscious perinephritic hypertensive dogs. Unlike the hypotensive effect of nicardipine, that of CS-905 has a gradual onset and is long-lasting, with little increase in the heart rate and plasma renin activity (PRA). The lack of both tachycardia and increase of PRA is probably mostly due to the slow onset of antihypertensive action following CS-905.
CS - 905,(±)-3 - (1 - 二苯基甲基氮杂环丁烷 - 3 - 基)5 - 异丙基2 - 氨基 - 1,4 - 二氢 - 6 - 甲基 - 4 - (间硝基苯基)-3,5 - 吡啶二甲酸酯,是一种新型二氢吡啶类钙阻滞剂。CS - 905和尼卡地平口服给药时,均可使清醒的肾周围性高血压犬的血压呈剂量依赖性下降。与尼卡地平的降压作用不同,CS - 905的降压作用起效缓慢且持久,心率和血浆肾素活性(PRA)升高不明显。心率加快和PRA升高均未出现,可能主要是由于CS - 905降压作用起效缓慢所致。